Anthroium predicts human exposure early in drug discovery through physics-based modeling and virtual human models.
Anthroium predicts how a drug behaves in the human body.
We connect molecular design to real-world exposure using mechanistic models—so teams can see risks earlier and make better decisions in the drug discovery process.
Drug discovery tools can predict how a molecule behaves.
But they do not show how that molecule behaves inside a human body.
Human exposure depends on many interacting processes—absorption, transport, metabolism,
and distribution—not just molecular properties. This gap makes early exposure decisions difficult and uncertain.
![[background image] image of abstract digital artwork (for a blockchain and cryptocurrency)](https://cdn.prod.website-files.com/697e53925c3f556475b1ad1e/698624df0ea583b32bfac64e_1.%20Futuristic%20tech%20setup%20with%20molecular%20design.png)
Molecular-level structure and behavior as the foundation for downstream exposure reasoning.
Biological processes governing absorption, distribution, metabolism, and excretion modeled explicitly.
Integration of mechanistic inputs into human-scale exposure and PBPK-ready frameworks.
Human exposure is one of the most common causes of drug failure.
And it remains hard to predict early in discovery.
ADME tests are often run separately. Each result is useful on its own, but they are not connected. Without integration, exposure risk is judged piece by piece instead of as one biological system.
Many exposure predictions rely on historical correlations. They work within known chemical space—but often break when structure or biology changes. Without mechanistic grounding, it is hard to know why exposure is limited or how to fix it.
Clear exposure insight often comes only after animal studies or late modeling. By then, chemistry strategy and program direction are already set. Late exposure surprises are expensive.
Human exposure is not driven by one property. It emerges from interacting processes—transport, metabolism, distribution, and physiology. Without modeling these interactions directly, early exposure reasoning remains uncertain.
OUR SOLUTION
Anthroium models the biological processes that determine human exposure.
Instead of relying on correlations or isolated property screens, we integrate mechanistic ADME within a virtual human framework.
![<subject>[background image] image of robotics lab (for a robotics and automation)</subject>](https://cdn.prod.website-files.com/697e53925c3f556475b1ad1e/698653c21c3ac48067141eac_Physicochemical%20properties%20and%20mechanistic%20models%20V2.png)
Human exposure is not controlled by one property. It results from many biological processes working together across the body from molecular, cellular and organs.
This complexity explains why exposure limits are often discovered late—
and why mechanistic modeling is needed earlier in discovery.
WORKFLOW
Anthroium introduces mechanistic exposure reasoning early in discovery.
We integrate with molecular modeling, in vitro assays, and early PK studies—helping teams identify exposure limits before committing to in vivo programs.
1) Molecular Input
2) Transport Processes
3) Metabolic Pathways
4) Tissue Distribution
5) Integrated Exposure Reasoning
6) Decision-Grade Outputs
Most discovery platforms optimize molecules or predict individual properties.
They are not designed to model human exposure as an integrated biological system.
Anthroium was built specifically for exposure reasoning. We model transport, metabolism,
tissue distribution, and physiology together—within one mechanistic framework.
Anthroium is designed around human exposure as the primary outcome, rather than treating exposure as a downstream inference from isolated properties.
ADME processes are modeled as interacting biological mechanisms, enabling exposure reasoning that reflects how biology actually behaves across scales.
Mechanistic components are composed within a virtual human representation, providing physiological context for how molecular behavior translates into exposure.
Models are constructed to preserve mechanistic transparency, supporting scientific understanding of why exposure is limited—not just whether it is.
Outputs are structured to integrate directly with physiologically based pharmacokinetic workflows, supporting downstream translational modeling and decision-making.
Anthroium is designed to augment existing molecular modeling, experimental assays, and PK tools rather than replace them.
Anthroium is a mechanistic modeling layer for human exposure. We connect molecular behavior to biological systems—so teams can reason about exposure earlier and with greater clarity.
Mechanistic by construction: Exposure is modeled as an emergent biological outcome, not inferred from isolated properties.
Decision-oriented: Designed to support earlier prioritization, redesign, and go/no-go decisions around exposure feasibility.
Built to integrate: Complements existing computational, experimental, and pharmacokinetic workflows rather than replacing them.
Platform Roadmap
Anthroium follows a disciplined development path that prioritizes mechanistic fidelity, validation, and real-world applicability over rapid feature expansion.
Anthroium is currently developing physics-based physicochemical and mechanistic models to identify the dominant absorption, distribution, metabolism, and excretion pathways governing drug exposure.These models operate at the molecular and process level and are integrated to support early exposure reasoning and identification of exposure-limiting mechanisms.
Decisions Supported
Which ADME mechanisms are most likely to dominate for a given molecule?
Stage 1 capabilities integrate with molecular modeling, in vitro assays, and early PK studies—introducing mechanistic exposure insight upstream without replacing existing discovery workflows.
Decisions Supported
How should experimental and modeling resources be prioritized early?
Where will additional data most reduce uncertainty?
Reusable, organ-specific models of absorption, transport, metabolism, and tissue disposition provide physiological context beyond chemistry-level reasoning.
Decisions Supported
Why do similar molecules behave differently across tissues?
Which organs or processes limit systemic exposure?
Mechanistic ADME components are integrated into whole-body PBPK frameworks to predict human concentration–time profiles and evaluate dosing and interaction scenarios.
Decisions Supported
Is predicted human exposure sufficient for efficacy and safety?
How sensitive is exposure to dosing assumptions?
Physiological and biological variability is incorporated to explore inter-individual exposure differences across patient populations and clinical scenarios.
Decisions Supported
How does exposure vary across populations and dosing strategies?
Physiological and biological variability is incorporated to explore inter-individual exposure differences across patient populations and clinical scenarios.
Decisions Supported
How does exposure vary across populations and dosing strategies?
What exposure outcomes should be expected across clinical contexts?
Anthroium is led by scientists and advisors with deep experience in mechanistic modeling, drug discovery, and translational decision-making. Platform development is guided by scientific rigor, interpretability, and real-world applicability.
![[headshot] image of customer (for a real estate tech)](https://cdn.prod.website-files.com/697e53925c3f556475b1ad1e/697e87b3e87f2b5e9437bef6_Ryan%20Dykstra.jpeg)
![[headshot] image of customer (for a construction company)](https://cdn.prod.website-files.com/697e53925c3f556475b1ad1e/697e87b35250c131f83b04de_Michael%20Chen.jpeg)
We are looking for scientists and engineers who think across scales, from molecule to organ to human, and are motivated to reduce clinical trial failure through first-principles modeling.
We are currently engaging with early team members across scientific and technical roles. Early team members will help shape the scientific foundation of the platform and contribute directly to how mechanistic modeling is applied in drug discovery.
If you are interested, please email careers@anthroium.com with your CV or resume and a brief statement outlining your background and areas of expertise or interest.
![[interface] image of employee interacting with hr software (for a hr tech)](https://cdn.prod.website-files.com/697e53925c3f556475b1ad1e/699c8ec888e158475ee78e1a_99757429-4314-4434-8d3c-62e992bae245.avif)
Anthroium works with scientific and development teams interested in advancing exposure reasoning earlier in drug discovery. Current engagements focus on collaborative pilot programs, platform feedback, and strategic discussions aligned with mechanistic modeling and translational decision-making.
![[background image] image of abstract digital artwork (for a blockchain and cryptocurrency)](https://cdn.prod.website-files.com/697e53925c3f556475b1ad1e/697e6d300b2dbf2dc7b9361f_ec0e7ba6-1a2b-4693-aa80-097f68da3b13.avif)
Pilot engagements allow partners to apply Anthroium’s mechanistic ADME framework to real discovery challenges. These collaborations focus on exposure-limiting mechanisms, feasibility assessment, and early-stage decision support.
Best for: Discovery teams evaluating exposure risk early or exploring new modeling approaches.
Anthroium collaborates with academic and industry scientists interested in advancing mechanistic exposure modeling, validation strategies, and translational methodology.
Best for: Researchers and groups focused on ADME, pharmacokinetics, and systems-level modeling.
![[background image] image of a futuristic laboratory setting (for a ai biotech company)](https://cdn.prod.website-files.com/697e53925c3f556475b1ad1e/697e613e67eac3c5c230ea1c_a5f70abd-7884-44a9-8d56-552e8085da83.avif)
Anthroium engages with strategic partners and investors aligned with long-term platform development, scientific rigor, and integration into real discovery workflows.
Best for: Organizations and individuals interested in supporting or shaping platform evolution.
We welcome inquiries from scientific teams, collaborators, and strategic partners interested in mechanistic exposure modeling. Please share a brief overview of your interest, and a member of the Anthroium team will follow up.
The Anthroium MVP identifies dominant ADME mechanisms and computes exposure for primary small-molecule pathways, including passive diffusion and hepatic clearance. Later platform stages extend this framework to additional mechanisms and physiological complexity.
No. Anthroium is designed to complement existing molecular modeling, experimental assays, and pharmacokinetic workflows by introducing mechanistic exposure reasoning earlier in discovery.
Anthroium is currently focused on early discovery and preclinical stages, where molecular design decisions remain flexible and exposure-related risks can still be addressed efficiently.
Traditional PBPK tools are typically applied later in development. Anthroium focuses on mechanistic ADME integration earlier in discovery, generating PBPK-ready outputs while preserving interpretability at the molecular level.
At present, Anthroium capabilities are delivered through pilot programs and services-assisted engagements, enabling close scientific collaboration as the platform continues to evolve.
Anthroium is designed as a general mechanistic framework and can be applied across therapeutic areas where exposure plays a critical role in efficacy and safety.
If you’re interested in contributing and growing a career with Anthroium, please email careers@anthroium.com with your CV or resume along with a short note describing your background, what interests you about Anthroium, and what you would want to work on. Please use the subject line: “Anthroium – [Your Name] – Career Interest.”
